Ask AI
ProCE Banner Activity

Not Always a Last Resort: The Evidence for Basal Insulin

Clinical Thought

A leading expert reviews the utility of basal insulin for patients with type 2 diabetes and ongoing work in the development of newer, more convenient therapies.

Released: July 17, 2023

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the Endocrine Society

ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk. 

Novo Nordisk

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research 
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, 
AdventHealth Translational Research Institute 
Adjunct Professor of Medicine, Johns Hopkins University School of Medicine 
Orlando, Florida 

Richard E. Pratley, MD: researcher (paid to institution): Dompe, Hanmi Pharmaceutical, Novo Nordisk; consultant/speaker (paid to institution): Bayer AG, Dexcom, Endogenex, Gasherbrum Bio, Hengrui, Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceutical, Sun Pharmaceutical Industries.